Efinaconazole in Onychomycosis

Area of Science:

• Dermatology
• Mycology
• Pharmacology

Background:

• Onychomycosis is a common fungal nail infection causing discoloration and thickening.
• Efinaconazole 10% topical solution is an FDA-approved treatment for onychomycosis.
• It targets ergosterol synthesis, crucial for fungal cell membrane integrity.

Purpose of the Study:

• To evaluate the efficacy and safety of efinaconazole 10% topical solution for onychomycosis.
• To compare its in vitro activity and nail penetration with other antifungal agents.
• To identify patient subsets likely to respond favorably to the treatment.

Main Methods:

• In vitro antifungal activity assays.
• Pharmacokinetic studies assessing nail bed delivery.
• Analysis of Phase I and III clinical trial data, including post-hoc analyses.
• Evaluation of patient characteristics influencing treatment response.

Main Results:

• Efinaconazole 10% exhibits potent in vitro activity against dermatophytes, comparable to terbinafine and amorolfine.
• Enhanced nail penetration due to its physicochemical properties.
• Favorable response observed in patients with mild disease, lower BMI, and treated tinea pedis.

Conclusions:

• Efinaconazole 10% topical solution is a safe and effective treatment for adult and pediatric onychomycosis.
• Recommended as a first-line option for mild-to-moderate cases, pediatric patients, and those with comorbidities.
• Offers satisfactory mycological and clinical cure rates with a favorable safety profile.